Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk
Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.“These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” Vlado Perkovic, MB, PS, PhD,
Source: healio.com
